ABSTRACT In a patient with severe carpal tunnel syndrome and a significant deficiency of vitamin B6, the evidence for the deficiency was an extraordinarily low basal specific activity of the glutamic-oxaloacetic transaminase of the erythrocytes (EGOT). This enzyme was also deficient in pyridoxal phosphate. The patient was treated with the recommended dietary allowance of pyridoxine, 2 mg/day, for 11 weeks, then 100 mg/day for 12 weeks, a placebo for 9 weeks, and again pyridoxine at 100 mg/day for 11 weeks. Sixty-one monitorial assays of EGOT over 48 weeks supported the followin nterpretations. (i) His diet permitted the development of a debilitating carpal tunnel syndrome. (ii) Treatment with pyridoxine at 2 mg/day reduced the deficiency of EGOT activity from about 70% to 50%, maintained a deficiency of pyridoxal phosphate, and relieved but allowed a marginal syndrome. (iii) Treatment at 100 mg/day for 12 weeks nearly achieved a "ceiling" level of EGOT and eliminated the deficiency of pyridoxal phosphate. (iv) After placebo for 7 weeks, the deficiencies of EGOT activity and pyridoxal phosphate reappeared, and clinical symptoms become worse. (v) Retreatment at 100 mg/day reestablished a "ceiling" EGOT, with no deficiency of pyridoxal phosphate, and the patient was asymptomatic. These data a so support the concept that a deficiency of vitamin B6 is significant in the etiology of the carpal tunnel syndrome. Mechanistically, a state of deficiency of the coenzyme seems to lower the level of the apoenzyme; a state of no deficiency of the coenzyme regulates a ceiling level of the transaminase. The latter state is presumably desired for health.
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An exceptional study has been made of our 22nd patient who had a severe carpal tunnel syndrome. This study was cooperative and effectively combined both the biochemical and the clinical aspects. We describe herein the biochemical aspects which constitute evidence for an association of a deficiency of vitamin B6 with the carpal tunnel syndrome as based on a crossover clinical study. The companion and detailed clinical aspects will be described elsewhere.
Ellis et al. (1) cooperatively found a deficiency of vitamin B6, as pyridoxal phosphate, in a group of 10 patients who had a clinical status associated with the carpal tunnel syndrome. These patients showed a significant (P < 0.001) deficiency of vitamin B6, as determined by the basal specific activities of the glutamic-oxaloacetic transaminase (L-aspartate:2-oxoglutarate aminotransferase, EC 2.6.1.1) of the erythrocytes (EGOT) in comparison with those of a control group. The detection and quantitation of the deficiency of pyridoxal phosphate was based upon the principle of unsaturation and saturation of a coenzyme-apoenzyme system-for example, EGOT. These 10 patients were treated with pyridoxine. Disappearance of the deficiency of pyridoxal phosphate was observed and, notably, the level of EGOT activity increased by 55-68% during 2-4 weeks, respectively. Apparently, more apoenzyme had been biosynthesized, because the specific activities were significantly higher (P < 0.001 at 4 weeks) than before treatment. Because clinical evaluation showed an improvement after treatment with pyridoxine, it was concluded that the deficiency and the syndrome were related.
In a cooperative study (2) , 11 additional patients were selected by clinical criteria as having the carpal tunnel defect, and they were also found to be deficient (P < 0.001) in vitamin B6, by the same differential assay of EGOT.
The deficiencies of these patients without treatment over 6 weeks were essentially unchanged, and the deficiency had disappeared in a single patient. Seventeen clinical signs and symptoms, by scores, had disappeared or decreased (0.001 < P < 0.01) after 6 weeks of treatment; after 11 weeks, greater clinical improvement was evident (P < 0.001). Criteria included the use of the Preston pinch gauge for evaluation of hand performance, which was improved (0.001 < P < 0.01) after 11 weeks. Again, the deficiency appeared to be related to the neurological syndrome.
A entially assayed in the absence and in the presence of added coenzyme. A significant increase in the specific activity of the enzyme system in the presence of added coenzyme measures a deficiency of the coenzyme at the site or of the vitamin in the tissue." This principle was tentatively designated as the Coenzyme-Apoenzyme-System (CAS principle). The EGOT data on patient 22 are in Table 1 and may be summarized as follows. Twelve blood samples were taken over 5 weeks for control determinations and were considered as adequately representative of his B% status on his dietary life style. It was not feasible to have a nutritional analysis of his diet which was that of a "country-family." It was important that, under his life-style, he had developed such a severe neurological disease that the symptoms strongly interfered with his work and with his day and night habits. The control mean (-SD) basal specific activity was 0.22 ± 0.04 (n = 12). This value is significantly lower (P < 0.001) than that of typical individuals who commonly serve as normal controls, which was 0.30 i 0.05 (n = 21) (8) . The mean control deficiency was 23 + 6% which is significantly higher (P < 0.05) than the 18 ± 5% for a group of 21 control individuals (8 (2 mg) of pyridoxine for 10-12 weeks. This period resulted from our study (9) which showed that periods of up to 12 weeks of supplementation with pyridoxine were necessary to reach a stable level ("ceiling") of the specific activity of EGOT, which was 0.69 + 0.09. When patient 22 was treated with 2 mg of pyridoxine per day for 11 weeks, his mean basal specific activity was 0.31 + 0.03 and his deficiency was 14 + 8%. Biochemically, these two values are not significantly different from 0.30 + 0.05 and 18 + 5% for the basal specific activity and deficiency, respectively, for the group of 21 typical individuals who commonly serve as normal controls, only 6 of whom had a supplementation of pyridoxine ranging from 1 to 5 mg per day (8) . Clinically, patient 22 showed definite improvement after 11 weeks of treatment with the RDA, but there still remained positive clinical evidence of the syndrome. Biochemically, the mean specific activity of 0.31 ± 0.03 (n = 15) was essentially unchanged for 9 weeks, and this level was barely 50% of the ceiling level. It is evident that the RDA of 2 mg per day was too low for this patient for his biochemical status and was submarginal for his clinical status.
Patient 22 was then treated with 100 mg of pyridoxine daily for 12 weeks. As expected, the basal specific activity increased over the first 6 weeks and then became reasonably stabilized. The mean specific activity for the entire 12-week period was 0.49 ± 0.09, which was about 70% of the ceiling level but, notably, the deficiency had disappeared as shown by the value -1 + 7%. The difference between the basal specific activity and the deficiency values for the treatments at 2 mg and 100mg per day are all significant (P < 0.01 and P < 0.001). We believe that, had patient 22 been maintained on 100 mg/day for longer than 12 weeks, his basal specific activity would have leveled off closer to 0.69, because a value of 0.65 was observed once after 12 weeks; his specific activity did reach the ceiling in the final treatment period after the placebo.
Clinically, there was improvement on the 100 mg/day regimen over that on the RDA (2 mg), and two orthopedic surgeons independently concluded that "surgery of the carpal tunnel was unnecessary."
The patient was then placed on a matching placebo for 9 weeks. After 7 weeks, his biochemical status had deteriorated as evidenced by a mean specific activity of 0. 
